Bullish Case: After a -33% sixty-day drawdown to $58.09, bad news (Wainua ATTR miss attributed to Pfizer-drug confound, Redemplo competition) is largely in the price. Call volume dominates 73%, Helium's density peak sits at $55-57.5 with upside mass to $60-62.5, and the term structure's 40-43% mid-curve versus 58.6% front IV implies event premium already burned off — a Tryngolza uptake beat or zilganersen/olezarsen positive readout could drive IV relief plus a $65-70 grind.

Bearish Case: Market IV remains backwardated (58.6% Sept vs 46.7% Apr 2027) with put skew steep (60P at 70 vol), signaling traders still pay up for downside protection. Arrowhead's Redemplo safety edge threatens olezarsen's competitive moat before it even ramps, and the Wainua failure taints the antisense franchise narrative. Helium's odds curve shows fat left-tail mass below $45 that the market underprices.

Potential Outcomes:

1. 35% Rangebound $53-62: No fresh catalysts; IV bleeds from 58.6% toward 50% (falsified by break below $52.50).
2. 25% Competitive repricing -10-20%: Redemplo filing/launch data forces olezarsen share assumptions lower; put skew steepens further.
3. 18% Recovery +10-20%: Tryngolza script momentum plus ESSENCE/balanced olezarsen data lift spot toward $65-70.
4. 12% Franchise doubt -20-35%: Another ATTR/triglyceride trial stumble mirrors Wainua; deep-OTM put vol (>100%) already hints at this tail.
5. 7% Pipeline beat +25-40%: zilganersen/olezarsen approval or broad-label win; Jan $75 calls (IV 47.7%) reprice sharply.
6. 3% Macro: SPY vol spike drags IONS -5-8% idiosyncratically.

September 05, 2026